Colwill Karen, Galipeau Yannick, Stuible Matthew, Gervais Christian, Arnold Corey, Rathod Bhavisha, Abe Kento T, Wang Jenny H, Pasculescu Adrian, Maltseva Mariam, Rocheleau Lynda, Pelchat Martin, Fazel-Zarandi Mahya, Iskilova Mariam, Barrios-Rodiles Miriam, Bennett Linda, Yau Kevin, Cholette François, Mesa Christine, Li Angel X, Paterson Aimee, Hladunewich Michelle A, Goodwin Pamela J, Wrana Jeffrey L, Drews Steven J, Mubareka Samira, McGeer Allison J, Kim John, Langlois Marc-André, Gingras Anne-Claude, Durocher Yves
Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health Toronto ON Canada.
Department of Biochemistry, Microbiology, and Immunology University of Ottawa Ottawa ON Canada.
Clin Transl Immunology. 2022 Mar 23;11(3):e1380. doi: 10.1002/cti2.1380. eCollection 2022.
Antibody testing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been instrumental in detecting previous exposures and analyzing vaccine-elicited immune responses. Here, we describe a scalable solution to detect and quantify SARS-CoV-2 antibodies, discriminate between natural infection- and vaccination-induced responses, and assess antibody-mediated inhibition of the spike-angiotensin converting enzyme 2 (ACE2) interaction.
We developed methods and reagents to detect SARS-CoV-2 antibodies by enzyme-linked immunosorbent assay (ELISA). The main assays focus on the parallel detection of immunoglobulin (Ig)Gs against the spike trimer, its receptor binding domain (RBD) and nucleocapsid (N). We automated a surrogate neutralisation (sn)ELISA that measures inhibition of ACE2-spike or -RBD interactions by antibodies. The assays were calibrated to a World Health Organization reference standard.
Our single-point IgG-based ELISAs accurately distinguished non-infected and infected individuals. For seroprevalence assessment (in a non-vaccinated cohort), classifying a sample as positive if antibodies were detected for ≥ 2 of the 3 antigens provided the highest specificity. In vaccinated cohorts, increases in anti-spike and -RBD (but not -N) antibodies are observed. We present detailed protocols for serum/plasma or dried blood spots analysis performed manually and on automated platforms. The snELISA can be performed automatically at single points, increasing its scalability.
Measuring antibodies to three viral antigens and identify neutralising antibodies capable of disrupting spike-ACE2 interactions in high-throughput enables large-scale analyses of humoral immune responses to SARS-CoV-2 infection and vaccination. The reagents are available to enable scaling up of standardised serological assays, permitting inter-laboratory data comparison and aggregation.
针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的抗体检测在检测既往暴露情况和分析疫苗引发的免疫反应方面发挥了重要作用。在此,我们描述了一种可扩展的解决方案,用于检测和定量SARS-CoV-2抗体,区分自然感染和疫苗接种诱导的反应,并评估抗体介导的对刺突蛋白-血管紧张素转换酶2(ACE2)相互作用的抑制作用。
我们开发了通过酶联免疫吸附测定(ELISA)检测SARS-CoV-2抗体的方法和试剂。主要检测方法集中于平行检测针对刺突三聚体、其受体结合域(RBD)和核衣壳(N)的免疫球蛋白(Ig)G。我们实现了一种替代中和(sn)ELISA的自动化,该方法可测量抗体对ACE2-刺突蛋白或-RBD相互作用的抑制作用。这些检测方法已根据世界卫生组织参考标准进行校准。
我们基于单点IgG的ELISA能够准确区分未感染和感染个体。对于血清流行率评估(在未接种疫苗的队列中),如果在3种抗原中检测到≥2种抗体则将样本分类为阳性,这提供了最高的特异性。在接种疫苗的队列中,观察到抗刺突蛋白和-RBD(但不包括-N)抗体增加。我们提供了用于手动和自动平台上血清/血浆或干血斑分析的详细方案。snELISA可以在单点自动进行,提高了其可扩展性。
通过高通量测量针对三种病毒抗原的抗体并鉴定能够破坏刺突蛋白-ACE2相互作用的中和抗体,能够对SARS-CoV-2感染和疫苗接种的体液免疫反应进行大规模分析。这些试剂可用于扩大标准化血清学检测的规模,允许实验室间的数据比较和汇总。